PHARMACEUTICAL COMPOSITION OF THE GLUCOSYLCERAMIDE SYNTHASE INHIBITOR ELIGLUSTAT FOR THE TREATMENT GAUCHER'S DISEASE COMPRISING ADJUSTING THE INDIVIDUAL THERAPEUTICAL DOSE TO THE P450 METABOLISM OF THE PATIENT

The hemitartrate salt of a compound represented by the following structural formula:(Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	PETERSCHMITT, Judith, SIEGEL, Craig, WILLIS, Chris, MARSHALL, John, HARIANAWALA, Abizer, LIU, Hanlan, CHENG, Seng, COPELAND, Diane P, BHARDWAJ, Renu, SKELL, Jeffrey, PALACE, Gerard, KOCHLING, Jianmei
Format:	Patent
Sprache:	eng ; fre ; ger
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The hemitartrate salt of a compound represented by the following structural formula:(Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline Formula (I) Hemitartrate, and using it to inhibit glucosylceramide synthase or lowering glycosphingolipid concentrations in subjects to treat a number of diseases, are also discussed. Pharmaceutical compositions are also described.